Sign In
Buy SLDB
$8.30
-0.0300 (-0.360%)
At Close: Jun 22, 2026
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
12:29pm, Tuesday, 18'th Feb 2025
On Tuesday, Solid Biosciences Inc. SLDB released initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment
Solid Biosciences Announces Pricing of Underwritten Offering
07:00am, Tuesday, 18'th Feb 2025
CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
06:45am, Tuesday, 18'th Feb 2025
— Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple ad
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
06:27pm, Tuesday, 21'st Jan 2025
Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia
08:30am, Tuesday, 21'st Jan 2025
- Only dual route gene transfer therapy in development to treat Friedreich's ataxia with FDA IND clearance and Fast Track designation -
- Duchenne : Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 08'th Jan 2025
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
11:26am, Wednesday, 08'th Jan 2025
Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia.
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia -
Solid Biosciences Added to the Nasdaq Biotechnology Index
04:05pm, Monday, 23'rd Dec 2024
CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
01:52pm, Friday, 13'th Dec 2024
Wedbush initiated coverage on Solid Biosciences, Inc. SLDB, a gene therapy company focused on treating Duchenne muscular dystrophy (DMD).
Solid Biosciences to Participate at Upcoming Investor Conferences
08:00am, Tuesday, 26'th Nov 2024
CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences to Present at the Jefferies London Healthcare Conference
08:00am, Thursday, 14'th Nov 2024
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
04:05pm, Wednesday, 06'th Nov 2024
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 02'nd Oct 2024
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and c
